Effect of perioperative anti-HER2 therapy on early breast cancer study – biological phase.
Disease site: Breast cancer
Treatment modality: Systemic therapy
Status: In follow up
EPHOS-B is a phase III, multicentre, three group, randomised controlled trial to determine whether pre-operative treatment of HER2+ breast cancer patients with anti-HER2 therapy inhibits proliferation or increases apoptosis.
Part 1 of EPHOS-B closed to recruitment in August 2013. In this part of the study, HER2+ patients received either perioperative trastuzumab, perioperative lapatinib, or standard care. Part 2 immediately superseded part 1, and patients recevied either perioperative trastuzumab, a combination of perioperative lapatinib and trastuzumab, or standard care. Part 2 of EPHOS-B closed to recruitment in September 2015. Perioperative treatment consists of 11 days pre-operative treatment and further post-operative treatment, and participants will be followed up for 10 years.
Chief Investigator: Professor Nigel Bundred, University of Manchester/University Hospital of South Manchester NHS Foundation Trust
ICR-CTSU Scientific Lead: Professor Judith Bliss
Trial management contact: [email protected]
Sponsors: The Institute of Cancer Research and University of Manchester/University Hospital of South Manchester NHS Foundation Trust
Funding: Cancer Research UK (CRUK/08/002) and GlaxoSmithKline
Further information including recruitment progress is available from the following link:
Patient friendly information is available from the following link:
Publications and presentations
Bliss JM, Robison LE, Webster-Smith MF, Emson MA, Kilburn LS, Smith IE, Robertson J, Dowsett M, Bundred NJ, Cameron DA, Vidya R, Horgan K, Evans AA, Kokan JS, Pinhel I, A'Hern R; on behalf of the POETIC and EPHOS-B Trialists. A trial model for the future in the search for personalised medicine – the UK POETIC and EPHOS-B perioperative trials experience. Cancer Res. 2011; 71(24 Suppl): Abstract number OT2-03-04.